US20180028427A1 - Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations - Google Patents
Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations Download PDFInfo
- Publication number
- US20180028427A1 US20180028427A1 US15/722,448 US201715722448A US2018028427A1 US 20180028427 A1 US20180028427 A1 US 20180028427A1 US 201715722448 A US201715722448 A US 201715722448A US 2018028427 A1 US2018028427 A1 US 2018028427A1
- Authority
- US
- United States
- Prior art keywords
- heparan sulfate
- cosmetological
- formulation
- weight
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the invention relates to a new process for the purification of heparan sulfate.
- the present invention also relates to cosmetological and dermatological preparations making use of heparan sulfate.
- Heparans are extracted from heparinoids which constitutes a by-product in the purification of heparin from pig intestinal mucosa. They are structural isomers formed during synthesis of glycosaminoglycanes (GAGS); highly sulfated and epimerised structures are typical of heparin, while highly epimerised and less N- and O-sulfated structures are typical of heparin-like structures presenting low anticoagulant activity.
- GGS glycosaminoglycanes
- the present invention relates to cosmetological and dermatological preparations comprising heparan sulfate, and their use as whitening, anti-wrinkle, lenitive and anti-oxidant agent. It has been surprisingly found that heparan sulfate is effective in the treatment of the above mentioned conditions.
- the invention is directed to medical devices making use of heparan sulfate in the cosmetological and dermatological field.
- the present invention is directed to a process for the purification of heparan sulfate, which process allows the use of pure heparan sulfate in dermatological and cosmetological applications.
- the cosmetological and dermatological preparations according to the invention make use of purified heparan sulfate.
- purification of heparan sulfate is an important step in order to remove residual compounds which are extracted with heparan sulfate but present different characteristics.
- the purification process of the invention is characterized by the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin under conditions which result in selective desorption of heparan sulfate.
- the anion exchange resin is preferably a strong base macroporous anion exchange resin such as, for example, LewatitTM S 6328 A.
- the adsorption is performed by mixing a sufficient amount of resin beads.
- the amount of beads is higher than 15 g of resin per gram of heparan sulfate, more preferably is comprised between 18 and 25 g resin per gram of heparan sulfate.
- heparan sulfate is selectively desorbed by using an alkaline or alkaline earth metal salt, preferably an halogenide or an acetate.
- suitable salts are magnesium dichloride, magnesium diacetate, sodium chloride, sodium acetate, potassium chloride and potassium acetate.
- the pH of the salt solution is preferably comprised between 7.0 and 10.0.
- the concentration of the salt is important in order to achieve complete and selective desorption of heparan sulfate. A preferred range of concentration is comprised between 0.3 M and 1.0 M, more preferably between 0.5 M and 0.8 M. In fact, if the concentration of the salt is too low, the desorption of heparan sulfate is incomplete. If the concentration is too high, the desorption is not selective and, together with heparan sulfate, also highly sulfated compounds are desorbed.
- heparan sulfate is optionally further passed on a cationic resin and on a anionic resin.
- a cationic resin is Amberlite Forte IR 120TM.
- An example of a suitable cationic resin is Amberlite Forte IRA 410TM.
- heparan sulfate Purified heparan sulfate according to the invention was tested in various dermatological and cosmetological applications. More specifically, heparan sulfate was tested for whitening, lenitive and anti-age effects. In all these applications heparan sulfate showed a significant activity.
- a preferred embodiment of the present invention is directed to a cosmetological composition comprising heparan sulfate.
- the cosmetological compositions according to the invention comprise from 0.01% by weight to 5% by weight of heparan sulfate, more preferably from 0.05% by weight to 2% by weight, even more preferably from 0.1% by weight to 1.0% by weight.
- the molecular weight by weight (Mw) of the heparan sulfate suitable in the cosmetological and dermatological applications of the invention is preferably comprised between 6,000 and 12,000 Da.
- cosmetological compositions according to the invention optionally comprise other substances such as preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, which are usually included in cosmetological and dermatological compositions.
- compositions according to the present invention are used as anti-age product.
- Many anti-age products often claim their ability to induce an increase in cell proliferation or in the protein synthesis on fibroblasts, with a linked improvement in cell firmness and thickness.
- Fibroblasts are the main cell component in the connective tissue of the dermis and they are able to synthesize high amount of collagen and elastin, the main components of the dermis that play an essential role in the skin thickness and appearance.
- the increase in protein amount for cell stimulates the ability of fibroblasts to synthesize collagen and elastin.
- Oxidative stress is one of the main cause of aging process and is involved in the development of many serious human diseases. Exposure to UVA rays, pollutants, tobacco's smoke, as well as diet, drugs intake or pathologies can increase the level of oxidant activity in the skin cells or decrease the effectiveness of endogenous antioxidant systems. Following exposure to oxidative stress Reactive Oxygen Species (ROS) formation, damages to the cells membrane and to DNA may occur in the cell, leading to cell transformation or even death.
- ROS oxidative stress Reactive Oxygen Species
- compositions comprising heparan sulfate are effective both as anti-wrinkle compositions and as anti-oxidant compositions.
- the resin was washed, transferred in a column (diameter 3 cm, length 40 cm) and eluted with a 5% by weight solution of MgCl 2 at pH 8.5.
- the first 300 ml are collected, after which the solution did not show presence of heparan sulfate (negative reaction to quaternary ammonium).
- the suspension is left at 15° C. for 12 h. Then the solid is collected, dissolved in 50 ml of water and precipitated by adding 100 nil of acetone.
- Heparan sulfate is then dissolved in 100 ml of water and the solution is passed over a resin Amberlite Forte IR 120TM and then over a resin Amberlite Forte IRA 410 TM.
- the eluate is neutralized by adding a 5% by weight solution of NaOH until pH 6.
- Water is evaporated under vacuum, the solid is filtered on a 0.45 ⁇ m filter and lyophilised. Yield: 4.12 g.
- the in vitro whitening effect of HS was detected by measurement of melanin content on melanoma cells B16 (fibroblast-like cells able to produce melanin) after 6 days of contact with HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%).
- NC negative control
- PC positive control
- HS heparan sulphate sodium salt
- the test was performed in the single blind mode. 20 volunteers (age between 40-50 years) with aged spots where present (hand, forehead, arm, face, neck). The region with aged spots was divided in two zone: one for the treatment with tested substance, one with placebo. The spots were treated for 30 consecutive days: 1 application (1 mg of substance)/die on tested area (150-200 cm 2 ) [as per Colipa guideline].
- the tested substance was an emulsion of the following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.
- Placebo was an emulsion of the following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.
- MI Melanin Index by Mexameter MX 18
- Basophil cells when come in contact with irritant substances, give their biochemical response that is the secretion (by degranulation) of substances (such as histamine, leukotriens, proteolytic enzymes as hexosaminidase) that contribute to inflammatory events.
- substances such as histamine, leukotriens, proteolytic enzymes as hexosaminidase
- Inhibition in basophil cells degranulation is a measure of lenitive (anti-itching) effect of a substance.
- the in vitro lenitive effect of HS was detected by measurement of the release of ⁇ -hexosaminidase after 2 h of contact with HS at 4 different concentrations: 10 mg/ml (1%), 5 mg/ml (0.5%), 1 mg/ml (0.1%), 0.2 mg/ml (0.02%).
- the negative control was represented by untreated cells (cells without any substance).
- the positive control was represented by basophil degranulation stimul (by crosslinking the receptor Fc ⁇ RI with a specific polyclonal antibody against to the ⁇ -chain stimulate the degranulation).
- the maximal stimulation is: cell treated with 1% Triton X-100. The results are reported as Optical Density (OD) at 405 nm.
- HS heparan sulphate sodium salt
- ⁇ -hexosaminidase “natural” level, level without any contact with irritant substance is 0.054 (OD at 450 nm).
- HS alone (at different concentration) has the same effect of negative control, that means leaves the cell with their “natural” level of ⁇ -hexosaminidase. This confirms that HS has no effect on basophil cells degranulation.
- the test was performed in single blind mode. 20 volunteers (age between 36-52 years) were treated on a circumscribed treated zone of 1 cm 2 on the back of each volunteer: one for test substance application, one for placebo application, and one for control (untreated zone). The test was performed by a single application (2 mg of substance) on tested area (1 cm 2 ) [as per Colipa guideline]. Total time: 60 minutes after application
- Tested substance was an emulsion of following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.
- Placebo was an emulsion of following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.
- the transient erythemagenic reaction is induced by exposure to a known amount of UVB radiation coming from a Solar Stimulator.
- the evaluation (EI—Erythema Index by Mexameter MX 18) were made in the following way:
- the antioxidant effect of HS is detected by measurement of reduction of free radicals as Reactive Oxygen Species (ROS) after exposure to 3 different UVA irradiation for 1 minute and 30 seconds (1′ 30′′), for 3 minutes (3′) and for 4 minutes and 30 seconds (4′ 30′′), with HS at 7 different concentrations: 0.031 mg/ml (0.0031%), 0.063 mg/ml (0.0063%), 0.125 mg/ml (0.0125%), 0.250 mg/ml (0.0250%), 0.500 mg/ml (0.0500%), 1.000 mg/ml (0.1000%) and 9.000 mg/ml (0.9000%).
- the negative control (NC) was: untreated cells (cells without any substance).
- the positive control (PC) was: Vitamin C (0.15 mg/ml) (0.015%).
- Table VI shows the results obtained. It is evident that heparan sulphate sodium salt (HS) shows in vitro antioxidant effect.
- HS heparan sulphate sodium salt
- the efficacy of HS at 0.1% concentration is comparable or even higher than the efficacy of Vitamin C.
- the efficacy of HS is higher that Vitamin C even at prolonged exposure to UVA radiation (4′ 30′′).
- the mitogenic effect of HS is detected by measurement of fibroblast cells proliferation, measurement of protein synthesis after exposure for 48 hours and 72 hours, using HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%).
- the negative control (NC) is represented by untreated cells
- the positive control (PC) is: EGF (Epidermal Growth Factor) (10 ⁇ g/ml) (0.001%).
- heparan sulphate sodium salt shows in vitro cell proliferation and protein synthesis efficacy. The highest effect (18.2% for cell proliferation and 20.4% for protein synthesis) is observed after 72 hour from exposure at 0.05 mg/ml.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to cosmetological and dermatological compositions comprising heparan sulfate. The invention further discloses a process for the purification of heparan sulfate for dermatological and cosmetological applications, which process comprises the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin by using conditions which result in selective desorption of heparan sulfate. The cosmetological and dermatological compositions according to the invention show, inter alia, anti-age, lenitive, and whitening effect.
Description
- The invention relates to a new process for the purification of heparan sulfate. The present invention also relates to cosmetological and dermatological preparations making use of heparan sulfate.
- Heparans are extracted from heparinoids which constitutes a by-product in the purification of heparin from pig intestinal mucosa. They are structural isomers formed during synthesis of glycosaminoglycanes (GAGS); highly sulfated and epimerised structures are typical of heparin, while highly epimerised and less N- and O-sulfated structures are typical of heparin-like structures presenting low anticoagulant activity.
- It is known that endogenous proteoglycans (PG) play an important role in wound healing (V. Prathiba and S. Gupta: Cutaneous wound healing: Significance of proteoglycans in scar formation”. Current Science, vol. 78, no 6, 2000). However, the prior art does not describe the effect of administration of proteoglycans and, more specifically, of heparan sulfate in cosmetological and dermatological applications.
- The present invention relates to cosmetological and dermatological preparations comprising heparan sulfate, and their use as whitening, anti-wrinkle, lenitive and anti-oxidant agent. It has been surprisingly found that heparan sulfate is effective in the treatment of the above mentioned conditions.
- In a further embodiment, the invention is directed to medical devices making use of heparan sulfate in the cosmetological and dermatological field.
- In another preferred embodiment, the present invention is directed to a process for the purification of heparan sulfate, which process allows the use of pure heparan sulfate in dermatological and cosmetological applications.
- In a preferred embodiment, the cosmetological and dermatological preparations according to the invention make use of purified heparan sulfate. In fact, purification of heparan sulfate is an important step in order to remove residual compounds which are extracted with heparan sulfate but present different characteristics.
- The purification process of the invention is characterized by the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin under conditions which result in selective desorption of heparan sulfate.
- The anion exchange resin is preferably a strong base macroporous anion exchange resin such as, for example, Lewatit™ S 6328 A. The adsorption is performed by mixing a sufficient amount of resin beads. Preferably the amount of beads is higher than 15 g of resin per gram of heparan sulfate, more preferably is comprised between 18 and 25 g resin per gram of heparan sulfate.
- After adsorption on the anion exchange resin, heparan sulfate is selectively desorbed by using an alkaline or alkaline earth metal salt, preferably an halogenide or an acetate. Examples of suitable salts are magnesium dichloride, magnesium diacetate, sodium chloride, sodium acetate, potassium chloride and potassium acetate. The pH of the salt solution is preferably comprised between 7.0 and 10.0. The concentration of the salt is important in order to achieve complete and selective desorption of heparan sulfate. A preferred range of concentration is comprised between 0.3 M and 1.0 M, more preferably between 0.5 M and 0.8 M. In fact, if the concentration of the salt is too low, the desorption of heparan sulfate is incomplete. If the concentration is too high, the desorption is not selective and, together with heparan sulfate, also highly sulfated compounds are desorbed.
- After desorption from the anion exchange resin, heparan sulfate is optionally further passed on a cationic resin and on a anionic resin. An example of suitable anionic resin is Amberlite Forte IR 120™. An example of a suitable cationic resin is Amberlite Forte IRA 410™.
- Purified heparan sulfate according to the invention was tested in various dermatological and cosmetological applications. More specifically, heparan sulfate was tested for whitening, lenitive and anti-age effects. In all these applications heparan sulfate showed a significant activity.
- A preferred embodiment of the present invention is directed to a cosmetological composition comprising heparan sulfate.
- Preferably, the cosmetological compositions according to the invention comprise from 0.01% by weight to 5% by weight of heparan sulfate, more preferably from 0.05% by weight to 2% by weight, even more preferably from 0.1% by weight to 1.0% by weight.
- The molecular weight by weight (Mw) of the heparan sulfate suitable in the cosmetological and dermatological applications of the invention is preferably comprised between 6,000 and 12,000 Da.
- The cosmetological compositions according to the invention optionally comprise other substances such as preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, which are usually included in cosmetological and dermatological compositions.
- In a preferred embodiment, the compositions according to the present invention are used as anti-age product. Many anti-age products often claim their ability to induce an increase in cell proliferation or in the protein synthesis on fibroblasts, with a linked improvement in cell firmness and thickness.
- Fibroblasts are the main cell component in the connective tissue of the dermis and they are able to synthesize high amount of collagen and elastin, the main components of the dermis that play an essential role in the skin thickness and appearance. The increase in protein amount for cell stimulates the ability of fibroblasts to synthesize collagen and elastin.
- Another claim for anti-aging and protective cosmetics is their activity in counteracting oxidative stress and free-radicals release in the skin. Oxidative stress is one of the main cause of aging process and is involved in the development of many serious human diseases. Exposure to UVA rays, pollutants, tobacco's smoke, as well as diet, drugs intake or pathologies can increase the level of oxidant activity in the skin cells or decrease the effectiveness of endogenous antioxidant systems. Following exposure to oxidative stress Reactive Oxygen Species (ROS) formation, damages to the cells membrane and to DNA may occur in the cell, leading to cell transformation or even death.
- The induction of fibroblasts proliferation and protein synthesis in dermis cells are of great concern for actives targeted to anti-age topical products.
- It has been found that compositions comprising heparan sulfate are effective both as anti-wrinkle compositions and as anti-oxidant compositions.
- Organic sulfur, Uronic acid, Glucosamine, Optical rotation, total nitrogen and APTT were measured in accordance with the European Pharmacopeia, 4th edition. Electrophoresis was performed in accordance with R. Cappelletti et al. “A new Electrophoretic method for the separation of all Gags” Anal. Biochem. 99:311-315 (1979).
- Molecular mass (Mw) was determined by size exclusion chromatography (European Pharmacopoeia 4th ed.: 2.2.30 and 2.2.46 for chromatography techniques and 01/2002:0828 p. 1297 for method).
- 5 g of heparan sulfate from pig intestinal mucosa were dissolved in 200 ml of demineralised water. 90 g of Lewatit S 6238 A™ were added to the solution. The mixture was slowly stirred at room temperature for 72 h and then filtered. The filtrate was analysed and no heparan sulfate was detected.
- The resin was washed, transferred in a column (diameter 3 cm, length 40 cm) and eluted with a 5% by weight solution of MgCl2 at pH 8.5.
- The first 300 ml are collected, after which the solution did not show presence of heparan sulfate (negative reaction to quaternary ammonium).
- The solution is brought to pH=6 with a 10% solution of hydrochloric acid and heparan sulfate is precipitated by adding 600 ml of acetone. The suspension is left at 15° C. for 12 h. Then the solid is collected, dissolved in 50 ml of water and precipitated by adding 100 nil of acetone.
- Heparan sulfate is then dissolved in 100 ml of water and the solution is passed over a resin Amberlite Forte IR 120™ and then over a resin Amberlite Forte IRA 410 ™. The eluate is neutralized by adding a 5% by weight solution of NaOH until pH 6. Water is evaporated under vacuum, the solid is filtered on a 0.45 μm filter and lyophilised. Yield: 4.12 g.
- Analysis: Rotation=+50.62°. Organic S=9.07%. Uronic acid=31.97%. Glucosamine=37%. Total N=2.26%. AP i=6.31 U/mg. Mw=7538 Da (Before purification 8729 Da).
- The in vitro whitening effect of HS was detected by measurement of melanin content on melanoma cells B16 (fibroblast-like cells able to produce melanin) after 6 days of contact with HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%).
- The negative control (NC) was represented by untreated cells (cell without any substance). The positive control (PC) was represented by cells treated with Hydroquinone 5 μg/ml (0.0005%). On the basis of results obtained, heparan sulphate sodium salt (HS) shows in vitro whitening effect.
-
TABLE I Melanin Content (μg melanin/mg % Melanin Synthesis protein) Inhibition vs NC HS (0.01%) 41.9 10.3 HS (0.005%) 44.4 5.2 PC: Hydroquinone (0.0005%) 10.8 76.8 NC: untreated cells 46.8 — - The test was performed in the single blind mode. 20 volunteers (age between 40-50 years) with aged spots where present (hand, forehead, arm, face, neck). The region with aged spots was divided in two zone: one for the treatment with tested substance, one with placebo. The spots were treated for 30 consecutive days: 1 application (1 mg of substance)/die on tested area (150-200 cm2) [as per Colipa guideline].
- The tested substance was an emulsion of the following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.
- Placebo was an emulsion of the following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.
- The evaluation (MI—Melanin Index by Mexameter MX 18) was made in the following way:
-
- T0—basal value, value of Melanin Index before the application of substance.
- T15—value of Melanin Index after 15 days of substance application.
- T30—final value, value of Melanin Index at the end of test (after 30 days of substance application).
-
TABLE II T0 MI ± std dev T15 MI ± std dev T30 MT ± std dev HS 0.9% 229.09 ± 44.06 222.00 ± 58.37 220.81 ± 54.25 Placebo 199.89 ± 55.89 205.84 ± 55.95 215.07 ± 75.45 - The decrease of MI (Melanin Index) in the area treated with tested substance, versus MI treated with placebo, after 30 days of application, resulted statistically relevant (p<0.01). Hence the Whitening Effect of tested substance (emulsion with 0.9% Heparan Sulphate sodium salt) was confirmed.
- In Vitro—Degranulation Test on Basophil Cells with Cosmetic Raw Materials—Test Procedure
- Basophil cells, when come in contact with irritant substances, give their biochemical response that is the secretion (by degranulation) of substances (such as histamine, leukotriens, proteolytic enzymes as hexosaminidase) that contribute to inflammatory events.
- Inhibition in basophil cells degranulation is a measure of lenitive (anti-itching) effect of a substance. The in vitro lenitive effect of HS was detected by measurement of the release of β-hexosaminidase after 2 h of contact with HS at 4 different concentrations: 10 mg/ml (1%), 5 mg/ml (0.5%), 1 mg/ml (0.1%), 0.2 mg/ml (0.02%).
- The negative control (NC) was represented by untreated cells (cells without any substance). The positive control (PC) was represented by basophil degranulation stimul (by crosslinking the receptor FcεRI with a specific polyclonal antibody against to the α-chain stimulate the degranulation). The maximal stimulation (degranulation) is: cell treated with 1% Triton X-100. The results are reported as Optical Density (OD) at 405 nm.
-
TABLE III release of β-hexosaminidase OD at 450 nm NC: untreated cells 0.054 PC: basophil degranulation 0.117 Max Stimulation 0.377 HS 10 mg/ml 0.066 HS 5 mg/ml 0.059 HS 1 mg/ml 0.062 HS 0.2 mg/ml 0.061 HS 10 mg/ml + PC 0.061 HS 5 mg/ml + PC 0.055 HS 1 mg/ml + PC 0.110 HS 0.2 mg/ml + PC 0.112 - On the basis of results obtained, heparan sulphate sodium salt (HS) shows in vitro lenitive effect.
- The β-hexosaminidase “natural” level, level without any contact with irritant substance is 0.054 (OD at 450 nm). HS alone (at different concentration) has the same effect of negative control, that means leaves the cell with their “natural” level of β-hexosaminidase. This confirms that HS has no effect on basophil cells degranulation.
- When the cells come in contact with an irritant substance (positive control) the value increase at 0.117, or higher to 0.377 when in contact with Triton X-100 (1%).
- When the cells come in contact both with an irritant substance (positive control) and HS the level of β-hexosaminidase decrease in a dose dependent way, with best efficacy with HS at 0.5% and 1%, hence HS has a lenitive (anti-itching) effect.
- The test was performed in single blind mode. 20 volunteers (age between 36-52 years) were treated on a circumscribed treated zone of 1 cm2 on the back of each volunteer: one for test substance application, one for placebo application, and one for control (untreated zone). The test was performed by a single application (2 mg of substance) on tested area (1 cm2) [as per Colipa guideline]. Total time: 60 minutes after application
- Tested substance was an emulsion of following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.
- Placebo was an emulsion of following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.
- The transient erythemagenic reaction is induced by exposure to a known amount of UVB radiation coming from a Solar Stimulator. The evaluation (EI—Erythema Index by Mexameter MX 18) were made in the following way:
-
- T0—basal value, value of Erythema Index after UVB radiation and before the application of substance
- T15—value of Erythema Index after 15 minutes from substance application
- T30—value of Erythema Index after 30 minutes from substance application
- T60—value of Erythema Index after 60 minutes from substance application
-
TABLE IV T0 EI ± std T15 EI ± std T30 EI ± std T60 EI ± std dev dev dev dev Tested Substance 455.75 ± 64.63 439.55 ± 82.67 421.59 ± 72.31 406.39 ± 77.06 Placebo 453.21 ± 71.50 430.26 ± 76.22 415.69 ± 67.42 415.79 ± 75.18 -
TABLE V T0 vs T15 T0 vs T30 T0 vs T60 Tested Substance −4.19 −8.29 −11.24 Placebo −5.36 −8.29 −8.58 - The decrease of EI (Erythema Index) in the area treated with tested substance, versus EI treated with placebo, after 60 minutes from application, resulted statistically relevant (p<0.1), and is statistically relevant (p<0.01) the decrease after 60 minutes versus basal value. Hence the Lenitive (redness reduction) Effect of tested substance (emulsion with 0.9% Heparan Sulphate sodium salt) has been confirmed.
- In vitro Evaluation of the anti-ageing activity of cosmetic products through the investigation of their anti-oxidant and protective activity against UVA on human keratinocytes cell cultures.
- The antioxidant effect of HS is detected by measurement of reduction of free radicals as Reactive Oxygen Species (ROS) after exposure to 3 different UVA irradiation for 1 minute and 30 seconds (1′ 30″), for 3 minutes (3′) and for 4 minutes and 30 seconds (4′ 30″), with HS at 7 different concentrations: 0.031 mg/ml (0.0031%), 0.063 mg/ml (0.0063%), 0.125 mg/ml (0.0125%), 0.250 mg/ml (0.0250%), 0.500 mg/ml (0.0500%), 1.000 mg/ml (0.1000%) and 9.000 mg/ml (0.9000%). The negative control (NC) was: untreated cells (cells without any substance). The positive control (PC) was: Vitamin C (0.15 mg/ml) (0.015%).
- Table VI shows the results obtained. It is evident that heparan sulphate sodium salt (HS) shows in vitro antioxidant effect. The efficacy of HS at 0.1% concentration is comparable or even higher than the efficacy of Vitamin C. The efficacy of HS is higher that Vitamin C even at prolonged exposure to UVA radiation (4′ 30″).
-
TABLE VI Heparan Sulphate Sodium Salt Vit C mg/ml mg/ml Exposure 9.000 1.000 0.500 0.250 0.125 0.063 0.031 0.15 ROS Inhibition 1′30″ UVA 30.7 38.7 30.6 28.0 23.5 25.4 25.3 33.5 % 3′00″ UVA 31.6 35.7 29.1 22.9 14.2 21.8 20.1 31.4 4′30″ UVA 26.3 30.4 24.7 18.1 10.3 13.7 6.2 12.7 - The mitogenic effect of HS is detected by measurement of fibroblast cells proliferation, measurement of protein synthesis after exposure for 48 hours and 72 hours, using HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%). The negative control (NC) is represented by untreated cells, the positive control (PC) is: EGF (Epidermal Growth Factor) (10 μg/ml) (0.001%).
-
TABLE VII % cell proliferation vs NC 48 h 72 h PC: EGF (10 μg/ml) (0.001%) 112.5 121.6 HS 0.1 mg/ml (0.01%) 110.5 118.1 HS 0.05 mg/ml (0.005%) 106.7 118.2 % protein synthesis vs NC 48 h 72 h PC: EGF (10 μg (0.001%) 116.6 119.0 HS 0.1 mg/ml (0.01%) 103.1 113.2 HS 0.05 mg/ml (0.005%) 110.2 120.4 - On the basis of results obtained, heparan sulphate sodium salt (HS) shows in vitro cell proliferation and protein synthesis efficacy. The highest effect (18.2% for cell proliferation and 20.4% for protein synthesis) is observed after 72 hour from exposure at 0.05 mg/ml.
Claims (14)
1-13. (canceled)
14. A method of reducing itching, the method comprising applying a formulation comprising heparan sulfate to a patient in need thereof.
15. The method of claim 14 , wherein the formulation comprises from 0.01 to 5% by weight heparan sulfate.
16. The method of claim 14 , wherein the formulation comprises from 0.05 to 2% by weight heparan sulfate.
17. The method of claim 14 , wherein the formulation comprises from 0.1 to 1% by weight heparan sulfate.
18. The method of claim 14 , wherein the heparan sulfate has a molecular weight between 6,000 and 12,000 Da.
19. The method of claim 14 , wherein the formulation further comprises one or more of the following ingredients: preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, and other components which are included in cosmetological and dermatological formulations.
20. The method of claim 14 , wherein the formulation is an emulsion.
21. A method for reducing free radicals as Reactive Oxygen Species (ROS) and increasing cell proliferation and protein synthesis, the method comprising applying a formulation comprising heparan sulfate to a patient in need thereof.
22. The method of claim 21 , wherein the formulation comprises from 0.01 to 5% by weight heparan sulfate.
23. The method of claim 21 , wherein the formulation comprises from 0.05 to 2% by weight heparan sulfate.
24. The method of claim 21 , wherein the formulation comprises from 0.1 to 1% by weight heparan sulfate.
25. The method of claim 21 , wherein the heparan sulfate has a molecular weight between 6,000 and 12,000 Da.
26. The method of claim 21 , wherein the formulation further comprises one or more of the following ingredients: preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, and other components which are included in cosmetological and dermatological formulations.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/722,448 US20180028427A1 (en) | 2008-11-20 | 2017-10-02 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08169547 | 2008-11-20 | ||
EP08169547.0 | 2008-11-20 | ||
PCT/EP2009/062582 WO2010057710A2 (en) | 2008-11-20 | 2009-09-29 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
US13/129,030 US9440099B2 (en) | 2008-11-20 | 2009-09-29 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
US15/228,150 US20160338935A1 (en) | 2008-11-20 | 2016-08-04 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
US15/722,448 US20180028427A1 (en) | 2008-11-20 | 2017-10-02 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/228,150 Division US20160338935A1 (en) | 2008-11-20 | 2016-08-04 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180028427A1 true US20180028427A1 (en) | 2018-02-01 |
Family
ID=41587870
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/129,030 Active 2031-03-25 US9440099B2 (en) | 2008-11-20 | 2009-09-29 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
US15/228,150 Abandoned US20160338935A1 (en) | 2008-11-20 | 2016-08-04 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
US15/722,448 Abandoned US20180028427A1 (en) | 2008-11-20 | 2017-10-02 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/129,030 Active 2031-03-25 US9440099B2 (en) | 2008-11-20 | 2009-09-29 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
US15/228,150 Abandoned US20160338935A1 (en) | 2008-11-20 | 2016-08-04 | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
Country Status (14)
Country | Link |
---|---|
US (3) | US9440099B2 (en) |
EP (2) | EP2679278B1 (en) |
JP (3) | JP2012509289A (en) |
KR (1) | KR101669528B1 (en) |
DK (2) | DK2679278T3 (en) |
ES (2) | ES2650937T3 (en) |
HR (2) | HRP20140862T1 (en) |
HU (1) | HUE035362T2 (en) |
LT (1) | LT2679278T (en) |
NO (1) | NO2679278T3 (en) |
PL (2) | PL2346573T3 (en) |
PT (2) | PT2679278T (en) |
SI (2) | SI2346573T1 (en) |
WO (1) | WO2010057710A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2679278T3 (en) * | 2008-11-20 | 2018-02-03 | ||
FR3000067B1 (en) * | 2012-12-21 | 2016-05-13 | Oreal | C-XYLOSIDE COMPOUNDS, COMPOSITIONS AND THEIR USE FOR DEPIGMENTING THE SKIN |
JP6321786B2 (en) | 2013-05-16 | 2018-05-09 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Heparan sulfate |
US10493012B2 (en) | 2014-11-19 | 2019-12-03 | Agency For Science, Technology And Research | Cosmetic use of heparan sulphate |
SG11201704085QA (en) | 2014-11-19 | 2017-06-29 | Agency Science Tech & Res | Heparan sulphates for use in repair and/or regeneration of skin |
ITUB20160156A1 (en) * | 2016-02-05 | 2017-08-05 | Laboratori Derivati Organici Spa | COMPOSITIONS INCLUDING A MIXTURE OF GLYCOSAMINOGLICANS AND THEIR USE IN COSMETIC AND DERMATOLOGICAL COMPOSITIONS |
CN108329405B (en) * | 2018-02-08 | 2020-06-23 | 黄石市典雅生物科技有限公司 | Method for protecting and purifying heparin sodium in resin adsorption state |
CN111909288B (en) * | 2020-08-13 | 2021-09-03 | 山东辰龙药业有限公司 | Refining method of heparin sodium |
KR20220096932A (en) | 2020-12-31 | 2022-07-07 | 주식회사 유연테크 | Dehumidifying cyclone dryer that combines dust removal and dehumidification |
WO2024072942A2 (en) * | 2022-09-29 | 2024-04-04 | Adora Animal Health Corporation | Skin penetrating formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5935599A (en) * | 1996-10-28 | 1999-08-10 | The Board Of Trustees Of The University Of Illinois | Polymer-associated liposomes for drug delivery and method of manufacturing the same |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63150209A (en) * | 1986-12-15 | 1988-06-22 | Kanebo Ltd | Skin cosmetic |
IT1212143B (en) * | 1987-06-26 | 1989-11-08 | Crinos Industria Farmaco | COMPOSITION WITH TRICHOGENIC ACTIVITY. |
JPH0696514B2 (en) * | 1987-07-15 | 1994-11-30 | 鐘紡株式会社 | Skin cosmetics |
JPH06104620B2 (en) * | 1987-07-15 | 1994-12-21 | 鐘紡株式会社 | Skin cosmetics |
DK505488D0 (en) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | MEDIUM AND USE OF SAME |
FR2643909B1 (en) * | 1989-03-03 | 1993-01-22 | Bioetica Sa | BASIC COMPOSITION FOR THE PREPARATION OF A COSMETIC COMPOSITION FORMING A HAIR COMPOSITION AND COSMETIC COMPOSITION FORMING A HAIR COMPOSITION THUS PREPARED, CONTAINING HEPARIN OR HEPARANE SULPHATE |
JPH03161416A (en) * | 1989-11-21 | 1991-07-11 | Kanebo Ltd | Skin cosmetic |
JP2931083B2 (en) * | 1990-11-22 | 1999-08-09 | ポーラ化成工業株式会社 | Skin cosmetics |
JPH05310548A (en) * | 1992-05-13 | 1993-11-22 | Taisho Pharmaceut Co Ltd | Skin external preparation |
GB9318288D0 (en) * | 1993-09-03 | 1993-10-20 | Nycomed Imaging As | Improvements in or relating to contrast agents |
SE9402531L (en) | 1994-07-19 | 1996-01-20 | Medicarb Ab | wound healing agent |
JPH0899861A (en) * | 1994-09-30 | 1996-04-16 | Kose Corp | Skin external agent |
US5989874A (en) * | 1995-03-27 | 1999-11-23 | Tayca Corporation | Humectant, antistatic agent, dispersant and film-forming agent having polysaccharide as active principle, preparation process of polysaccharides, and Kliebsiella ocytoca TNM-3 strain |
US6537977B1 (en) * | 1995-09-19 | 2003-03-25 | Seikagaku Corporation | Anti-inflammatory agent |
JP3687277B2 (en) * | 1997-06-10 | 2005-08-24 | サンスター株式会社 | Whitening cosmetics |
GB9913237D0 (en) * | 1999-06-08 | 1999-08-04 | K C L Enterprises Limited | Product |
JP4754066B2 (en) * | 2000-12-22 | 2011-08-24 | 株式会社林原生物化学研究所 | Anti-joint disorder |
JP2003171256A (en) * | 2001-12-03 | 2003-06-17 | Nonogawa Shoji Kk | Skin care preparation |
DE10161149B4 (en) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Use of heparin-containing ophthalmic agent |
US20070129430A1 (en) * | 2003-10-07 | 2007-06-07 | Satomi Miyata | Agent for enhancing the production of collagen, their preparation and use |
DE102004036689A1 (en) * | 2004-07-28 | 2006-03-23 | Henkel Kgaa | Low-residue deodorant or antiperspirant stick based on an oil-in-water dispersion |
JP4975751B2 (en) * | 2005-10-13 | 2012-07-11 | グ、ジェニファー、エル. | Minerals, collagens and chelates and their production and use |
JP2007254316A (en) * | 2006-03-22 | 2007-10-04 | Seikagaku Kogyo Co Ltd | Hyaluronic acid (ha) matrix formation inhibitor |
JP4564471B2 (en) * | 2006-07-06 | 2010-10-20 | 株式会社コーセー | Composition suitable for external use |
ITMI20072237A1 (en) * | 2007-11-27 | 2009-05-28 | Sigea Srl | MIXED BUTIRRIC-FORMAL ESTERS OF ACID POLYSACCHARIDES, THEIR PREPARATION AND USE AS DERMOCOSMETICS |
NO2679278T3 (en) * | 2008-11-20 | 2018-02-03 |
-
2009
- 2009-09-29 NO NO13159487A patent/NO2679278T3/no unknown
- 2009-09-29 DK DK13159487.1T patent/DK2679278T3/en active
- 2009-09-29 PT PT131594871T patent/PT2679278T/en unknown
- 2009-09-29 ES ES13159487.1T patent/ES2650937T3/en active Active
- 2009-09-29 WO PCT/EP2009/062582 patent/WO2010057710A2/en active Application Filing
- 2009-09-29 SI SI200931013T patent/SI2346573T1/en unknown
- 2009-09-29 EP EP13159487.1A patent/EP2679278B1/en active Active
- 2009-09-29 PL PL09783522T patent/PL2346573T3/en unknown
- 2009-09-29 SI SI200931764T patent/SI2679278T1/en unknown
- 2009-09-29 HU HUE13159487A patent/HUE035362T2/en unknown
- 2009-09-29 KR KR1020117013681A patent/KR101669528B1/en active IP Right Grant
- 2009-09-29 JP JP2011536799A patent/JP2012509289A/en active Pending
- 2009-09-29 US US13/129,030 patent/US9440099B2/en active Active
- 2009-09-29 PL PL13159487T patent/PL2679278T3/en unknown
- 2009-09-29 DK DK09783522.7T patent/DK2346573T3/en active
- 2009-09-29 EP EP09783522.7A patent/EP2346573B1/en active Active
- 2009-09-29 LT LTEP13159487.1T patent/LT2679278T/en unknown
- 2009-09-29 ES ES09783522.7T patent/ES2507495T3/en active Active
- 2009-09-29 PT PT97835227T patent/PT2346573E/en unknown
-
2014
- 2014-06-06 JP JP2014117306A patent/JP6058588B2/en active Active
- 2014-09-11 HR HRP20140862AT patent/HRP20140862T1/en unknown
-
2016
- 2016-08-04 US US15/228,150 patent/US20160338935A1/en not_active Abandoned
- 2016-12-05 JP JP2016235665A patent/JP2017043638A/en active Pending
-
2017
- 2017-10-02 US US15/722,448 patent/US20180028427A1/en not_active Abandoned
- 2017-11-29 HR HRP20171861TT patent/HRP20171861T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5935599A (en) * | 1996-10-28 | 1999-08-10 | The Board Of Trustees Of The University Of Illinois | Polymer-associated liposomes for drug delivery and method of manufacturing the same |
Non-Patent Citations (1)
Title |
---|
H03161416 JP A * |
Also Published As
Publication number | Publication date |
---|---|
DK2679278T3 (en) | 2017-12-11 |
ES2650937T3 (en) | 2018-01-23 |
DK2346573T3 (en) | 2014-10-06 |
KR101669528B1 (en) | 2016-10-26 |
EP2679278A1 (en) | 2014-01-01 |
WO2010057710A9 (en) | 2011-08-18 |
HUE035362T2 (en) | 2018-05-02 |
ES2507495T3 (en) | 2014-10-15 |
PL2346573T3 (en) | 2014-12-31 |
PT2346573E (en) | 2014-09-25 |
JP2014159488A (en) | 2014-09-04 |
SI2346573T1 (en) | 2014-10-30 |
HRP20171861T1 (en) | 2018-01-26 |
NO2679278T3 (en) | 2018-02-03 |
EP2346573A2 (en) | 2011-07-27 |
SI2679278T1 (en) | 2018-02-28 |
JP2012509289A (en) | 2012-04-19 |
WO2010057710A2 (en) | 2010-05-27 |
JP6058588B2 (en) | 2017-01-11 |
KR20110086734A (en) | 2011-07-29 |
LT2679278T (en) | 2017-12-27 |
WO2010057710A3 (en) | 2011-06-03 |
US20160338935A1 (en) | 2016-11-24 |
EP2679278B1 (en) | 2017-09-06 |
JP2017043638A (en) | 2017-03-02 |
US9440099B2 (en) | 2016-09-13 |
PT2679278T (en) | 2017-12-13 |
PL2679278T3 (en) | 2018-02-28 |
US20110288047A1 (en) | 2011-11-24 |
EP2346573B1 (en) | 2014-06-25 |
HRP20140862T1 (en) | 2014-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9440099B2 (en) | Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations | |
JP2014159488A5 (en) | ||
KR100755798B1 (en) | A topical composition comprising extracts of feverfew tanacetum parthenium and method of treating and preventing inflammatory disorders using the composition | |
EP1049451B1 (en) | Use of compounds for protecting skin from uv induced immunosuppression | |
EP1863430B1 (en) | Composition based on vegetal extracts of ajuga reptans for preventing hair loss, stimulating the growth of hair, regulating the production of sebum. | |
CA2703532C (en) | Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications | |
KR101436199B1 (en) | Composition for Improving Skin Conditions Comprising Hordenine | |
US20070167517A1 (en) | Stabilized derivatives of ascorbic aicd | |
US20120245120A1 (en) | Zinc sucrose octasulfates, their preparation, and pharmaceutical and cosmetic uses thereof | |
KR20140012456A (en) | Composition for improving skin conditions comprising akebia saponin d | |
KR20160024527A (en) | Skin agent composition containing Rumex obtusifolius extract | |
KR20070096279A (en) | A cosmetic composition comprising rumex crispus l. extracts | |
Haxaire et al. | Effect of L‐4‐Thiazolylalanine (Protinol™) on skin barrier strength and skin protection | |
KR101460672B1 (en) | Composition for preventing hair damage containing the extract of mycoleptodonoides aitchisonii fruit body | |
JP3120086B2 (en) | Hair cosmetics for prevention of gray hair and blackening of gray hair | |
JPH05221834A (en) | Hair cosmetic for preventing gray hair and blackening gray hair | |
WO2024120853A1 (en) | Compositions comprising sanguisorba officinalis root extract and uses thereof | |
KR101460670B1 (en) | Acne preventing and treating composition containing the extract of mycoleptodonoides aitchisonii fruit body | |
KR100986128B1 (en) | A skin-care agent containing Coniogramme japonica extract | |
JPH02268192A (en) | Retinoic acid ester of d-desosamine, its production, medicine for human or veterinary use and cosmetic composite | |
JPH06256144A (en) | Hair cosmetic for preventing white hair and blacking white hair | |
KR20160025112A (en) | Skin agent composition containing Rumex obtusifolius extract | |
WO2007064966A2 (en) | Pharmaceutical and dermatocosmetic compositions comprising extract of durio zibethinus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |